8-K: Soligenix Receives EMA Agreement for Key Design of HyBryte Phase 3 Trial in Cutaneous T-Cell Lymphoma

Soligenix has secured agreement from the European Medicines Agency on the design of a confirmatory Phase 3 trial for HyBryte in treating early-stage cutaneous T-cell lymphoma, with patient enrollment expected to begin by the end of 2024.

Summary

• Soligenix has received agreement from the European Medicines Agency (EMA) on the key design components for a confirmatory Phase 3 study of HyBryte for early-stage cutaneous T-cell lymphoma (CTCL).
• The study, named FLASH2, will be a placebo-controlled trial enrolling approximately 80 patients in the US and Europe.
• Patient enrollment is targeted to begin by the end of 2024, with top-line results expected in the second half of 2026.
• The FLASH2 study will replicate the design of the first successful Phase 3 FLASH study but will extend the double-blind, placebo-controlled treatment to 18 weeks continuously.
• The primary efficacy endpoint will be assessed at the end of the 18-week treatment period, focusing on the percentage of patients achieving a partial or complete response.
• The company is also in discussions with the FDA regarding the study design, with the FDA preferring a longer duration comparative study over a placebo-controlled trial.
• Soligenix will proceed with the EMA-accepted protocol due to the shorter time to potential commercial revenue and the similar trial design to the first FLASH study.

Sentiment

Score: 8

Explanation: The document is positive due to the EMA agreement and the progress of the Phase 3 trial. The company has a clear path forward for HyBryte and a strong pipeline of other products. However, there are some risks and uncertainties, such as the ongoing discussions with the FDA.

Positives

• The EMA agreement validates the design of the confirmatory Phase 3 study for HyBryte.
• The study design is similar to the first successful Phase 3 FLASH study, increasing the likelihood of positive results.
• The extended 18-week treatment period in the FLASH2 study is expected to demonstrate HyBryte's increased effect over a longer treatment course.
• HyBryte has a benign safety profile, which is a strong driver of treatment choice for CTCL.
• The company anticipates accelerated enrollment due to previous trial experience and engagement with the CTCL community.
• The study has the potential to support marketing approvals worldwide.

Negatives

• The FDA prefers a longer duration comparative study, which could potentially delay or complicate the regulatory pathway.
• The company will need to continue discussions with the FDA to address their feedback on the study design.
• The study is not expected to complete until the second half of 2026, which is a long time for investors to wait for results.

Risks

• There is a risk that the second Phase 3 trial may not be successful, despite the positive results of the first trial.
• The FDA may not approve HyBryte based on the results of the FLASH2 study, or may require additional studies.
• The company may face challenges in enrolling the required number of patients in the study.
• There is a risk that the company may not be able to secure the necessary funding to complete the study.
• The company is subject to risks and uncertainties detailed in their filings with the SEC.

Future Outlook

The company plans to initiate the FLASH2 study in the second half of 2024 and anticipates top-line results in the second half of 2026. They will continue discussions with the FDA regarding the development path for HyBryte. The company also has other products in development with significant commercial potential.

Management Comments

• Brian Poligone, MD, PhD, stated that clinical studies with HyBryte have demonstrated strong and rapid efficacy with a very benign safety profile.
• Christopher Schaber, PhD, stated that CTCL is an orphan disease in urgent need of additional treatment options that are well-tolerated and safe over the long term.
• Christopher Schaber, PhD, also stated that the company anticipates being able to accelerate enrollment in support of this study.

Industry Context

This announcement is significant as it represents a key step forward in the development of HyBryte for CTCL, a rare disease with limited treatment options. The agreement with the EMA provides a clear path for regulatory approval in Europe, while discussions with the FDA continue. The company is also developing other products for rare diseases, which aligns with the industry trend of focusing on unmet medical needs.

Comparison to Industry Standards

• The first Phase 3 FLASH study showed a 49% response rate after 18 weeks of treatment, which is a strong result compared to other treatments for early-stage CTCL.
• Current treatments for CTCL often have significant side effects, including the risk of melanoma, while HyBryte has demonstrated a benign safety profile.
• The use of visible light in HyBryte is a key differentiator from other phototherapy approaches that use UV light, which is associated with a higher risk of cancer.
• The company is targeting a market with a significant unmet need, as there is no approved first-line therapy for early-stage CTCL.

Stakeholder Impact

• Shareholders will be impacted by the progress of the clinical trials and the potential for regulatory approvals.
• Patients with CTCL will benefit from the development of a new treatment option with a benign safety profile.
• Employees will be involved in the execution of the clinical trials and the commercialization of HyBryte.
• The company's partners and collaborators will be impacted by the success of the clinical trials and the commercialization of HyBryte.

Next Steps

• Initiate patient enrollment in the confirmatory Phase 3 study by the end of 2024.
• Continue discussions with the FDA regarding the study design.
• Complete the confirmatory Phase 3 study and analyze the results.
• Seek regulatory approvals for HyBryte in the US and Europe.
• Advance the development of other products in the pipeline.

Key Dates

Keywords

HyBryte, Cutaneous T-cell lymphoma, CTCL, Phase 3 trial, European Medicines Agency, EMA, FLASH2, Photodynamic therapy, Orphan drug, Dermatology